Noah Nathan Kochen

Dr. Noah Nathan Kochen


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2021 in npj Parkinson's Disease
Verified
Journal Article
Open access
PDF file
ABAnthony R Braun
Anthony R Braun
ELElly E. Liao
Elly E. Liao
MHMian Horvath
Mian Horvath
PKPrakriti Kalra
Prakriti Kalra
KAKaren Acosta
Karen Acosta
JSJonathan N. Sachs
Jonathan N. Sachs
We have developed a high-throughput drug discovery platform, measuring fluorescence resonance energy transfer (FRET) with fluorescent alpha-synuclein (αSN) biosensors, to detect spontaneous pre-fibrillar oligomers in living cells. Our two αSN FRET biosensors provide complementary insight into αSN oligomerization and conformation in order to improve the success of drug discovery campaigns for the treatment of Parkinson’s disease. We measure FRET by fluorescence lifetime, rather than traditional fluorescence intensity, providing a structural readout with greater resolution and precision. This facilitates identification of compounds that cause subtle but significant conformational changes in the ensemble of oligomeric states that are easily missed using intensity-based FRET. We screened a 1280-compound small-molecule library and identified 21 compounds that changed the lifetime by >5 SD. Two of these compounds have nanomolar potency in protecting SH-SY5Y cells from αSN-induced death, providing a nearly tenfold improvement over known inhibitors. We tested the efficacy of several compounds in a primary mouse neuron assay of αSN pathology (phosphorylation of mouse αSN pre-formed fibrils) and show rescue of pathology for two of them. These hits were further characterized with biophysical and biochemical assays to explore potential mechanisms of action. In vitro αSN oligomerization, single-molecule FRET, and protein-observed fluorine NMR experiments demonstrate that these compounds modulate αSN oligomers but not monomers. Subsequent aggregation assays further show that these compounds also deter or block αSN fibril assembly.

7 February 2023 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
APAnil K. Pandey
Anil K. Pandey
CBCaroline R. Buchholz
Caroline R. Buchholz
NKNoah Nathan Kochen
Noah Nathan Kochen
WPWill Pomerantz
Will Pomerantz
ABAnthony R Braun
Anthony R Braun
JSJonathan N. Sachs
Jonathan N. Sachs

10 July 2023 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
ELElly E. Liao
Elly E. Liao
MYMu Yang
Mu Yang
NKNoah Nathan Kochen
Noah Nathan Kochen
NVNagamani Vunnam
Nagamani Vunnam
ABAnthony R Braun
Anthony R Braun
JSJonathan N. Sachs
Jonathan N. Sachs

10 June 2025 in ACS Chemical Neuroscience
Verified
Journal Article
Open access
NKNoah Nathan Kochen
Noah Nathan Kochen
MMMarguerite Murray
Marguerite Murray
SZSophia Zafari
Sophia Zafari
NVNagamani Vunnam
Nagamani Vunnam
ELElly E. Liao
Elly E. Liao
JSJonathan N. Sachs
Jonathan N. Sachs
Pathological aggregates of TDP-43 are implicated in Alzheimer's disease, frontotemporal dementia, and amyotrophic lateral sclerosis. While therapeutic efforts have traditionally focused on mitigating end-stage TDP-43 aggregation, recent evidence highlights an upstream and potentially targetable event: the loss of functional nuclear TDP-43 multimers due to disrupted N-terminal domain (NTD) interactions. To address this, we developed fluorescence lifetime (FLT)-based FRET biosensors to monitor TDP-43 multimerization in living cells that couple a full-length TDP-43 FLT-FRET biosensor screen with an NTD-deletion counter screen, forming the foundation of a novel high-throughput screening (HTS) platform. Screening the 2682 compound FDA-approved Selleck library, we identified the small molecule ketoconazole, which stabilizes functional nuclear TDP-43 multimers in an NTD-dependent manner with low micromolar potency. Ketoconazole rescues TDP-43 mislocalization and aggregation, restores SREBP2 mRNA levels under TDP-43 overexpression, improves neuronal health, and partially restores motor function in a TDP-43 C. elegans model. These findings establish both the biosensors and the HTS platform as innovative tools for TDP-43 drug discovery and support an exciting translational approach for targeting TDP-43 proteinopathies.

24 August 2022 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
NKNoah Nathan Kochen
Noah Nathan Kochen
VVVivek Vasandani
Vivek Vasandani
DSDarren Seaney
Darren Seaney
APAnil K. Pandey
Anil K. Pandey
MWMichael A. Walters
Michael A. Walters
JSJonathan N. Sachs
Jonathan N. Sachs

8 March 2024 in Proteins: Structure, Function, and Bioinformatics
Verified
Journal Article
Open access
NKNoah Nathan Kochen
Noah Nathan Kochen
DSDarren Seaney
Darren Seaney
VVVivek Vasandani
Vivek Vasandani
MMMarguerite Murray
Marguerite Murray
ABAnthony R Braun
Anthony R Braun
JSJonathan N. Sachs
Jonathan N. Sachs
Hydration plays a crucial role in the refolding of intrinsically disordered proteins into amyloid fibrils; however, the specific interactions between water and protein that may contribute to this process are still unknown. In our previous studies of alpha-synuclein (aSyn), we have shown that waters confined in fibril cavities are stabilizing features of this pathological fold; and that amino acids that hydrogen bond with these confined waters modulate primary and seeded aggregation. Here, we extend our aSyn molecular dynamics (MD) simulations with three new polymorphs and correlate MD trajectory information with known post-translational modifications (PTMs) and experimental data. We show that cavity residues are more evolutionarily conserved than non-cavity residues and are enriched with PTM sites. As expected, the confinement within hydrophilic cavities results in more stably hydrated amino acids. Interestingly, cavity PTM sites display the longest protein-water hydrogen bond lifetimes, three-fold greater than non-PTM cavity sites. Utilizing the deep mutational screen dataset by Newberry et al. and the Thioflavin T aggregation review by Pancoe et al. parsed using a fibril cavity/non-cavity definition, we show that hydrophobic changes to amino acids in cavities have a larger effect on fitness and aggregation rate than residues outside cavities, supporting our hypothesis that these sites are involved in the inhibition of aSyn toxic fibrillization. Finally, we expand our study to include analysis of fibril structures of tau, FUS, TDP-43, prion, and hnRNPA1; all of which contained hydrated cavities, with tau, FUS, and TDP-43 recapitulating our PTM results in aSyn fibril cavities.